Genes 2Me Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 15-06-2024
- Paid Up Capital ₹ 1.00 Cr
as on 15-06-2024
- Company Age 5 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 30.85 Cr
as on 15-06-2024
- Revenue -73.67%
(FY 2023)
- Profit -88.00%
(FY 2023)
- Ebitda -129.79%
(FY 2023)
- Net Worth 7.82%
(FY 2023)
- Total Assets -27.80%
(FY 2023)
About Genes 2Me
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹30.85 Cr.
Ritu Gupta and Neeraj Gupta serve as directors at the Company.
- CIN/LLPIN
U73200DL2019PTC354174
- Company No.
354174
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Aug 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Genes 2Me Private Limited offer?
Genes 2Me Private Limited offers a wide range of products and services, including Medical Laboratory Instruments, Corona Test Kit.
Who are the key members and board of directors at Genes 2Me?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ritu Gupta  | Director | 23-Aug-2019 | Current |
| Neeraj Gupta | Director | 23-Aug-2019 | Current |
Financial Performance and Corporate Structure Insights of Genes 2Me.
Genes 2Me Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 73.67% decrease. The company also saw a substantial fall in profitability, with a 88% decrease in profit. The company's net worth moved up by a moderate rise of 7.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Genes 2Me?
In 2023, Genes 2Me had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Imperial Life Sciences Private LimitedActive 18 years 6 monthsRitu Gupta and Neeraj Gupta are mutual person
Swernim Electronics Private LimitedActive 28 years 7 monthsRitu Gupta and Neeraj Gupta are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 12 Sep 2022 | ₹29.75 Cr | Open |
Hdfc Bank Limited Creation Date: 18 Aug 2022 | ₹1.10 Cr | Open |
How Many Employees Work at Genes 2Me?
Unlock and access historical data on people associated with Genes 2Me, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genes 2Me, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genes 2Me's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
